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10634 | RSC Adv., 2020, 10, 10634–lanyl aminopeptidase as
a biomarker for Pseudomonas aeruginosa in the
sputum of patients with cystic fibrosis using
exogenous volatile organic compound evolution
Ryan Thompson,a Dominic Stephenson,ab Hannah E. Sykes,a John D. Perry, b
Stephen P. Stanfortha and John R. Dean *a
A novel, rapid and sensitive analytical method has been developed and applied to 105 sputum samples from
patients with cystic fibrosis, including 5 samples from post-lung transplant patients. This new method is
specifically targeted to measure b-alanyl aminopeptidase activity which is characteristic of some
important Gram-negative pathogens. Of relevance to this study are Pseudomonas aeruginosa and
pathogens of the Burkholderia cepacia complex both of which are commonly associated with
respiratory infections as well as increased morbidity and mortality in adult cystic fibrosis patients. The
analytical method involves the addition of a novel enzyme substrate (i.e. 3-amino-N-(3-fluorophenyl)
propanamide) that interacts with b-alanyl aminopeptidase to generate an exogenous volatile organic
compound 3-fluoroaniline (LOD 0.02 mg mL1; LOQ 0.06 mg mL1). 3-Fluoroaniline was determined at
20 times above its calculated limit of quantification in the sputum samples by HS-SPME-GC-MS and
then the results compared with standard culture methods and bacterial identification using MALDI-TOF-
MS. Detection of 3-fluoroaniline was possible after only 8 h incubation of the sputum samples with
a 95% success rate; this increased to 100% at 24 h which was well within the typical routine timeframe
of 48 h. To our knowledge, this is the first demonstration of detection of P. aeruginosa by use of
a custom-designed substrate to liberate a detectable and unique VOC. The very high negative predictive
value (100% in this study) means such an assay could be appropriate as a screening technique for
patients who are not yet colonized by this pathogen.Introduction
Cystic brosis (CF) was rst identied as a distinct condition in
1938 by Dr Dorothy Anderson, who observed a pattern of cystic
brosis of the pancreas in patients with a history of respiratory
issues, subsequently leading to the identication of cystic
brosis as a distinct condition.1 CF is a common autosomal
recessive congenital disorder caused by mutations in the cystic
brosis transmembrane conductance regulator (CFTR) gene
responsible for anion transport, predominantly chloride &
bicarbonate, across epithelial cell membranes and mucociliary
clearance in respiratory airways.2
The absence or reduced function of the CFTR gene results in
extra thick mucosal secretions in organ systems with epithelial
cell linings, such as the lungs, digestive system, hepatobiliary
tracts, and vas deferens in males.3 Due to this abnormally
viscous lining, CF patients struggle to clear mucus from theiria University, Ellison Building, Newcastle
@northumbria.ac.uk
ital, Newcastle upon Tyne, NE7 7DN, UK
10645airways and are very susceptible to further lung colonization
and bacterial infections. In older children the rst symptoms
are oen a mix of abnormal liver function test results, pancre-
atic exocrine insufficiency, an absence of vas deferens devel-
opment in males, and persistent Staphylococcus aureus
respiratory infections. As patients age into young adulthood,
their symptoms oen progress into cirrhosis of the liver due to
chronic inammation, intermittent respiratory infections from
Pseudomonas aeruginosa, and established bronchiectasis. From
approximately age 20 onwards, patients will frequently have
established bronchiectasis associated with persistent respira-
tory infections with Gram-negative bacteria such as Pseudo-
monas aeruginosa and strains of the Burkholderia cepacia
complex. The necessity for lung transplantation is frequently
required for patients aged 30 onwards.4
Prognosis for CF patients is relatively poor in comparison to
healthy individuals, although is improving along with better
medical intervention. Based on data from the UK Cystic Fibrosis
Registry, half of CF patients born in 2017 would have a life
expectancy of approximately 47 years based upon current
treatment and management regimes. However, in 2017 theThis journal is © The Royal Society of Chemistry 2020
Paper RSC Advances
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
2 
M
ar
ch
 2
02
0.
 D
ow
nl
oa
de
d 
on
 3
/3
0/
20
20
 3
:1
1:
08
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinemedian age of death for CF patients in the UK was reported as
31 years.5 The most common cause of death in CF patients is
respiratory failure secondary to progressive lung disease, oen
caused by chronic infection. Due to an innate inability to clear
the thick mucus associated with the condition, CF patients are
susceptible to colonization by opportunistic pathogens that
pose little risk to non-compromised individuals. The pathology
associated with failure to clear microorganisms is exacerbated
by the patient's immune response, causing chronic inamma-
tion and tissue damage.6 In younger patients, the primary
bacteria responsible for infection are Staphylococcus aureus and
Haemophilus inuenzae,7 both of which cause signicant
damage to the airways either directly, or indirectly through the
immune inammatory response.8 As the condition progresses,
patients develop chronic bronchiectasis and become more
susceptible to infection from Gram-negative bacteria commonly
found in the environment, such as Achromobacter sp., Steno-
trophomonas maltophilia, Pseudomonas aeruginosa, and Bur-
kholderia cepacia complex strains.9,10 Additionally, there is an
increase in prevalence of nontuberculous Mycobacterium infec-
tions in patients with cystic brosis, particularly Mycobacterium
abscessus and Mycobacterium avium-intracellulare.11,12
Pseudomonas aeruginosa is by far the most common path-
ogen associated with respiratory infections in CF patients. In
2015, the UK national cystic brosis registry reported 49% of CF
patients aged 18 and above had a chronic P. aeruginosa infec-
tion,13 however some studies report the incidence of Pseudo-
monas infection as high as 60% in adult patients.14 Some studies
have shown that infection with P. aeruginosa can occur very early
in childhood. In longitudinal studies on children diagnosed
with CF, annual bronchoalveolar lavage cultures have shown
a high prevalence of P. aeruginosa (11%).7,15However, a further
study which monitored the presence of P. aeruginosa antibodies
found a higher incidence of infection at a younger age, as well as
in patients who tested culture negative suggesting that some P.
aeruginosa infections may be cleared naturally in younger
patients.16 The early detection and treatment of P. aeruginosa
infection is crucial and highly associated with a good prognosis.
Early intervention with a strict antibiotic regime has been
shown to achieve eradication of P. aeruginosa infection in
approximately 60% of cases,17 however if this short window is
missed, then infections are considered virtually impossible to
eliminate.17 Chronic P. aeruginosa infections have clear associ-
ations with an accelerated decline in lung function,18 and
increased mortality.19
Another important pathogen in CF patients are members of
the Burkholderia cepacia complex, a group of 22 members of the
Burkholderia genus. Infections from B. cepacia strains are
strongly associated with a severe decline in lung function in CF
patients, and an increased mortality rate.20 Patients infected
with B. cepacia complex strains may also develop a life threat-
ening systemic infection known as cepacia syndrome, where
eradication of the infection is impossible and has been highly
associated with post lung transplant mortality.21 The most
common members of the B. cepacia complex strains associated
with CF patients across Europe and Australasia are B. multi-
vorans and B. cenocepacia, whereas in the United States andThis journal is © The Royal Society of Chemistry 2020Canada, B. multivorans is the most prevalent.20 Interestingly,
Burkholderia gladioli, a non B. cepacia complex strain member of
the Burkholderia genus, has become more prominent in US CF
patients, but is very uncommon elsewhere.20
Pseudomonas and Burkholderia infections are predominantly
diagnosed in CF patients through the culturing of patient
respiratory samples, such as sputum, cough swab, and bron-
choalveolar lavages. Detection via culture relies on a plethora of
different selective media, as there is no one denitive protocol
for detection in hospitals so selective media panels and proto-
cols are oen developed in-house. Whilst culture methods have
proved successful thus far for the isolation of Pseudomonas and
Burkholderia, results are oen only available following 48–72 h
incubation, which when combined with the importance of
beginning patient treatment early, could be detrimental to
patient prognosis. The chromogenic culture medium
CHROMID® Pseudomonas contains a chromogenic substrate for
b-alanyl aminopeptidase, which is hydrolysed by P. aeruginosa
resulting in the formation of purple colonies aer 24 to 48 h of
incubation.22 For specimens from cystic brosis patients,
incubation can be extended up to 5 days. Our aim was to
therefore develop a rapid test for the detection of Pseudomonas
and Burkholderia from CF patient sputum samples, utilising b-
alanyl aminopeptidase activity. We have previously identied
that using targeted enzyme substrates, a unique exogenous
volatile organic compound can be liberated and detected using
either static headspace-solid phase micro-extraction-gas
chromatography-mass spectrometry, SHS-SPME-GC-MS23–26 or
static headspace multicapillary column-gas chromatography-
ion mobility spectrometry, SHS-MCC-GC-IMS.27 The use of
exogenous volatile organic compounds (VOCs) to distinguish 7
Gram-positive from 15 Gram-negative bacteria using the
enzyme substrates 2-amino-N-phenylpropanamide (to liberate
the VOC aniline) and 2-amino-N-(4-methylphenyl)propanamide
(to liberate the VOC p-toluidine) has been demonstrated.24
Similarly the approach has been applied for the analysis of
enzyme activity in Listeria species using the enzyme substrates
benzyl-a-D-mannopyranoside (to liberate the VOC benzyl
alcohol) and D-alanyl 3-uoroanilide (to liberate the VOC 3-u-
oroaniline).25 In addition, exogenous VOC detection has been
used to identify Salmonella in milk samples using the enzyme
substrates 2-chlorophenyl octanoate, phenyl a-D-galactopyr-
anoside and L-pyrrolidonyl uoroanilide which liberate the
VOCs 2-chlorophenol, phenol and 3-uoroaniline, respec-
tively.26 In this case however, b-alanyl aminopeptidase enzymes
work by catalysing the cleavage, via hydrolysis, of amino acids
from the amino (N) terminus of protein or peptide substrates.28
The presence of b-alanyl aminopeptidase activity is well docu-
mented in P. aeruginosa,29,30 and has subsequently led to studies
on the development of chromogenic and uorogenic substrates
targeting b-alanyl aminopeptidase activity as a method for the
detection of P. aeruginosa.31,32 There is also further evidence for
b-alanyl aminopeptidase activity in Burkholderia cepacia
complex and Serratia marcescens in studies using the b-alanyl
based 7-N-(b-alanyl)aminophenoxazin-3-one,31 9-(40-N-[b-alanyl]
aminophenyl)acridines,33 and 9-(40-N-[b-alanyl]aminophenyl)-
10-methylacridinium salts.34RSC Adv., 2020, 10, 10634–10645 | 10635
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View Article OnlineExperimental
Instrumentation and analysis
Gas chromatography-mass spectrometry (GC-MS) analyses were
performed using a ThermoFinnigan Trace GC Ultra paired with
a Polaris Q ion trap mass spectrometer (Thermo Fisher scien-
tic, Loughborough, UK) with Xcalibur 1.4 SR1 soware
package (Thermo Fisher). Separation of the analytes was ach-
ieved using an Agilent Technologies (Wokingham, UK) DB-5MS
column (30 m  0.25 mm internal diameter  0.25 mm lm
thickness), with the following temperature program: initial
oven temperature 50 C (hold 2 min), then a ramp to 250 C @
12.5 C min1, followed by a nal hold time of 2 min. The
Polaris Q ion trap mass spectrometer was set to full scan mode,
scanning a mass range of 33–200 m/z, with a scan event time of
0.31 s. The ion source temperature was maintained at 260 C,
and the mass transfer line was maintained at 250 C. Identi-
cation of VOCs was achieved using the National Institute of
Standards and Technology (NIST) reference library (NIST Mass
spectral library, version 2.0a, 2001) as well as the comparison of
the retention times andmass spectra of authentic standards. All
samples and standards were maintained at 37 C during SPME
sampling through the use of a water bath. All sputum samples
were stored within a 37 C incubator prior to analysis, and were
placed in the water bath 10 min prior to SPME analysis using an
85 mm polyacrylate bre (Sigma-Aldrich, Poole, UK) for
temperature maintenance. Standards which were not previously
stored at 37 C were placed in the water bath for a minimum of
30 min prior to sampling. Fibres were used for analyte extrac-
tion with a manual holder, and were exposed in the headspace
above all samples and standards for a total of 10 min. Following
the adsorption of analytes, the bre was immediately retracted
inside the needle and transported directly to the inlet of the GC-
MS. Analyte desorption was carried out by exposing the laden
bre within the split-splitless GC injection port at 250 C for
2 min. The inlet was set to split mode with a split ratio of 1 : 10,
with the helium carrier gas ow rate set to 1 mL min1. Fibres
were used for a maximum of 125 injections to ensure consis-
tency of readings. The same SPME bre type, method, and GC-
MS program was used for all samples, blanks, and standards,
throughout this study. The limit of detection (LOD) and limit of
quantication (LOQ) for HS-SPME-GC-MS were determined by
calculating the standard deviation (n ¼ 7) of the background
noise from the same retention time as the analyte. The LOD was
determined by multiplying the standard deviation by 3, and the
LOQ determined by multiplying by 10. Calibration curves were
determined by running known concentrations of each exoge-
nous VOC standard ranging from 0–100 mg mL1, giving a y ¼
mx + c value for sample concentration calculations. Due to
variability of adsorptive efficiency within the bres, a new cali-
bration for each analyte was required each time a new bre was
used.
Matrix Assisted Laser Desorption Ionization-Time of Flight-
Mass Spectrometry (MALDI-TOF-MS) analysis was performed
by a Microex LT mass spectrometer (Bruker Daltonik) using
the MALDI Biotyper soware package (version 3.0) with the10636 | RSC Adv., 2020, 10, 10634–10645reference database version 3.1.2.0. Isolated colonies were
identied down to either genus or species level through the
comparison of the sample generated spectra against that of an
in-house taxonomy spectra library. All distinct colony
morphologies isolated from the agar plates were subject to
analysis via MALDI-TOF-MS by initially transferring a thin lm
of the colony onto a single stainless steel target plate position.
The transferred colonies were covered with 1 mL of 70% formic
acid then once dried, 1 mL HCCA matrix solution: alpha-cyano-
4-hydroxycinnamic acid (10 mg HCCA dissolved in a solution of
475 mL distilled water, 500 mL acetonitrile, and 25 mL triuoro-
acetic acid). Following the addition of the matrix solution, the
samples were air dried prior to MALDI-TOF-MS analysis.
Materials & reagents
Brain heart infusion broth (CM1136), brain heart infusion agar
(CM1135), Columbia blood agar base (CM0331), CLED medium
with Andrades indicator (CM0423), Sabouraud dextrose agar
(CM0041), bacteriological agar no. 1 (LP001B), and Sputasol
(SR0233A) were all purchased from Oxoid, Basingstoke, UK.
Bacitracin (11072), chloramphenicol (C0378), Middlebrook 7H9
broth base (M0178), glycerol (G5516), 85 mm polyacrylate sol-
idphase micro-extraction bres, and N-methyl pyrrolidine
(NMP) (328634) were purchased from Sigma, Gillingham, UK.
Defribrinated horse blood (5% v/v, HB035) was purchased from
TCS biosciences, Buckingham, UK. Burkholderia cepacia selec-
tive agar (PP0160) was purchased from EO laboratories, Bon-
nybridge, UK. Yeast extract (03904110) was purchased from
bioMe´rieux, Marcy-l'E´toile, France. All bacteria used in this
study were acquired from the Freeman Hospital Microbiology
Department, Newcastle upon Tyne, UK. All P. aeruginosa strains
(except NCTC 12903) were all strains isolated from patients with
cystic brosis globally. All Burkholderia strains were part of the
Burkholderia cepacia complex.
Procedures for routine microbiological testing of cystic
brosis patient samples
Patient sputum specimens are routinely received for culture by
the Freeman Hospital Microbiology Department from clinics
which are run for CF patients. The samples used in this study
were aliquots of leover samples referred to the Microbiology
Department for routine analyses. No additional samples were
taken for the purposes of this study. Samples were anonymized,
except for the gender and age of the patient, by laboratory staff
with legitimate access to patient data. Anonymization meant
that patients could not be identied, and the results of this
independent study could not be used to affect patient
management in any way. Strict adherence to these conditions
meant that patient consent was not sought, in accordance with
the Medical Research Council Operational and Ethical Guide-
lines on the use of Human Tissue and Biological Samples for
Use in Research.
Upon sample reception, the sputum specimens were mixed
with an equal volume of sterile Sputasol and vortexed thor-
oughly until homogenization occurred. Homogenized samples
were cultured onto 8 different agar media to ensure goodThis journal is © The Royal Society of Chemistry 2020
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View Article Onlinedifferentiation and identication of organisms potentially
present. Then, 1 mL aliquots of the homogenous specimens
were transferred into sterile 20mL glass vials and refrigerated at
4 C until sample collection days.
Blood agar. Columbia blood agar base (Oxoid; CM0331,
Basingstoke, UK) was mixed with distilled water to a concen-
tration of 39 g L1 and autoclaved at 121 C for 15 min,
following sterilisation 5% (v/v) debrinated horse blood (TCS
biosciences; HB035, Buckingham, UK) was added before
dispensing approximately 20 mL per plate. Plates were streaked
using a 10 mL loop. Plates were then incubated within a constant
5% CO2 atmosphere, and maintained at 37 C.
Chocolate agar with bacitracin (CBAC). Columbia blood agar
base (Oxoid; CM0331, Basingstoke, UK) wasmixed with distilled
water to a concentration of 39 g L1 and autoclaved. Following
sterilisation, 5% (v/v) debrinated horse blood (TCS biosci-
ences; HB035, Buckingham, UK) was added, and the mixture
was reheated to 80 C to achieve haemolysis. Filter sterilised
bacitracin (Sigma; 11702) dissolved in N-methyl 2-pyrrolidone
(NMP) was then added to a nal concentration of 70 mg L1,
and the mixture dispensed to approximately 20 mL per plate.
Plates were streaked using a 10 mL loop. Plates were incubated
within a constant 5% CO2 atmosphere, and maintained at
37 C. Results were visually interpreted at both 24 and 48 h
incubation.
Chocolate agar. Columbia blood agar base (Oxoid; CM0331,
Basingstoke, UK) was mixed with distilled water to a concen-
tration of 39 g L1 and autoclaved. Following sterilisation, 5%
(v/v) debrinated horse blood (TCS biosciences; HB035, Buck-
ingham, UK) was added, and the mixture was reheated to 80 C
to achieve haemolysis. The mixture was then dispensed to
approximately 20 mL per plate. Plates were inoculated by rst
inoculating 2 mL of sterile water with 1 mL loop of sputum
sample, from this inoculated water a 10 mL loop was used for
streaking. Plates were incubated within a constant 5% CO2
atmosphere, and maintained at 37 C. Results were visually
interpreted at both 24 and 48 h incubation.
Cystine–lactose–electrolyte decient agar (CLED). CLED
medium with Andrades indicator (Oxoid; CM0423, Basingstoke,
UK) was mixed with distilled water to 36.2 g L1 and autoclaved.
Following sterilisation, the mixture was dispensed as standard.
Plates were streaked using a 10 mL loop. Plates were incubated
within a non-modied air atmosphere and maintained at 37 C.
Results were visually interpreted at both 24 and 48 h incubation.
Sabouraud agar with chloramphenicol (SAB). Sabouraud
dextrose agar (Oxoid; CM0041, Basingstoke, UK) wasmixed with
distilled water to 65 g L1 and autoclaved. Following auto-
claving, lter sterilised chloramphenicol heated at 100 C for
5 min (Sigma; C0378) was added to the mixture at 50 mg L1,
and the mixture dispensed. Plates were streaked using a 10 mL
loop. Plates were incubated within a non-modied air atmo-
sphere and maintained at 37 C. Results were visually inter-
preted following 5 days of incubation.
Aztreonam selective agar (AZTRE). Columbia blood agar
base (Oxoid; CM0331, Basingstoke, UK) was mixed with
distilled water to a concentration of 39 g L1 and autoclaved at
121 C for 15 min, following sterilisation 5% (v/v) debrinatedThis journal is © The Royal Society of Chemistry 2020horse blood (TCS biosciences; HB035, Buckingham, UK) was
added. Filter sterilised aztreonam (Azactam) was added to the
mixture at 15.625 mg L1 before dispensing. Plates were
streaked using a 10 mL loop. Plates were incubated within
a non-modied air atmosphere, and maintained at 37 C.
Results were visually interpreted at both 24 and 48 h
incubation.
Burkholderia cepacia agar (CEP). Burkholderia cepacia
selective agar was purchased ready-made (E&O labs, PP0160,
Bonnybridge, UK). Plates were inoculated through the lling of
a 3 mL pastette with the sputum sample, and subsequently
streaking 2 drops. Plates were incubated within a non-modied
air atmosphere, and maintained at 37 C. Results were visually
interpreted following 5 days of incubation.
Rapidly growing mycobacterium agar (RGM). RGM agar was
prepared as previously described.35Individual substrate testing against pure Pseudomonas
aeruginosa and Burkholderia cepacia complex strains
Sample vials were prepared by rst suspending bacterial cells in
sterile Brain Heart Infusion (BHI) broth and adjusting the
absorbance to 0.132 when measured at 600 nm. This gave an
inoculum of approximately 1–1.5  108 CFU mL1, equivalent
to 0.5 McFarland units. The sterile BHI broth was prepared by
dissolving 37 g of the powder mix into 1 litre of MilliQ water,
and sterilising the resulting mix via autoclave at 121 C for
15 min. Following this, 100 mL of 1  108 CFU mL1 stock was
added to 9.89 mL of sterile BHI broth. To this new bacterial
suspension, 10 mL of the chosen substrate i.e. 3-amino-N-(3-
uorophenyl)propanamide, 3-amino-N-(4-methylphenyl)prop-
anamide or 3-amino-N-phenylpropanamide (dissolved in NMP
to 100 mg mL1) was added. The nal volume of the sample
vials was 10 mL, with a nal bacterial inoculum of 1  106 CFU
mL1, and a nal substrate concentration of 100 mg mL1.
Sterile 20 mL glass vials with septum lids were used for all
samples. Once prepared, the sample vials were placed into an
incubator set to 37 C overnight, ranging from 20–24 h.
Following overnight incubation, the samples were then ana-
lysed via HS-SPME-GC-MS.Procedure for analysis of cystic brosis patient sputum
samples by HS-SPME-GC-MS
On sample collection days, 10 mL of BHI broth containing 100
mg mL1 of 3-amino-N-(3-uorophenyl)propenamide, 5 mg L1
amphotericin B (an anti-fungal) and 70 mg L1 bacitracin (a
combination of peptides that inhibit the growth of yeasts and
Gram-positive bacteria) was added to sample vials containing
1 mL specimen and then vortexed to thoroughly mix. Samples
were then collected and transported to the University Labora-
tories (within 1 h) where they were incubated at 37 C for set
time periods before analysis. Great care was taken to not disturb
or move the lids of the vials. Samples were placed into the
incubator in 20 min intervals, to account for the GC-MS runtime
and ensure that all samples were analysed following either 8 h
or 24 h incubation.RSC Adv., 2020, 10, 10634–10645 | 10637
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View Article OnlineProcedures for synthesis of enzyme substrates
The b-alanyl substrates 1a–c [as their triuoroacetate (TFA)
salts] were prepared from their corresponding Boc-protected
derivatives 2a–c.
Compounds 2a–c were synthesised from b-alanyl and an
appropriate aniline derivative using a mixed anhydride
coupling reaction. tert-Butyl (3-anilino-3-oxopropyl)carbamate
2a and 3-amino-N-phenylpropanamide (TFA salt) 1a have been
described previously.36
General procedure for mixed anhydride coupling
To Boc-b-alanyl (1.2 equivalents) in dry THF, N-methyl-
morpholine (1.05 equivalents) was added and reaction mixture
was cooled to 10 C and then stirred for 30 min. Isobutyl
chloroformate (1.05 equivalent) was then added, the mixture
was stirred (2 min) and then a pre-cooled (10 C) solution of
the appropriate aniline (1 equivalent) dissolved in THF (8 mL)
was added drop-wise. The mixture was stirred (2 h) at 10 C,
allowed to warm to room temperature and then stirred over-
night. The mixture was concentrated and water was added to
the residue. The mixture was extracted with CH2Cl2 (2  20 mL)
and the combined organic extracts were washed sequentially
with aqueous citric acid solution (0.1 M, 2  20 mL), aqueous
NaHCO3 solution (10%, 2  20 mL), water (2  20 mL), dried
(MgSO4) and concentrated to give the crude product. Recrys-
tallisation from methanol gave pure compounds as white
crystals.General procedure for Boc-deprotection
The appropriate Boc-protected substrate 2a–c was suspended in
dry CH2Cl2 and then triuoroacetic acid was added dropwise.
The resulting mixture was stirred (4 h) at room temperature and
evaporated. The resulting oil was triturated with diethyl ether
until a precipitate formed. The solid was collected and washed10638 | RSC Adv., 2020, 10, 10634–10645with diethyl ether giving the desired products (as their TFA
salts) as white, hydroscopic solids.Analytical data
3-Amino-N-(4-methylphenyl)propanamide, TFA salt 1b. 1H-
NMR (400 MHz; DMSO-d6) d: 10.1 (1H, s, N–H), 7.93 (3H,
broad s, –NH3
+), 7.44 (2H, d, J ¼ 8.8 Hz, Ar–H), 7.06 (2H, d, J ¼
8.8 Hz, Ar–H), 3.04 (2H, m, CH2), 2.66 (3H, t, J ¼ 6.8 Hz, CH2),
2.2 (3H, s, CH3);
13C-NMR (101 MHz; DMSO-d6) d: 168.6 (C]O),
159.1 (q, J ¼ 31 Hz, TFA), 136.9 (Ar–C), 132.7 (Ar–C), 129.6 (2 
Ar–C), 119.9 (2  Ar–C), 118.9 (q, J ¼ 297 Hz, TFA), 35.5 (CH2),
33.7 (CH2), 20.9 (CH3); HRMS: m/z found, 179.1177. C10H15N2O
[MH]+ requires, 179.1184.
3-Amino-N-(3-uorophenyl)propanamide, TFA salt 1c. 1H-
NMR (400 MHz; DMSO-d6) d: 10.42 (1H, s, N–H), 7.88 (3H,
broad s, –NH3
+), 7.57 (1H, d, J ¼ 11.6 Hz, Ar–H), 7.31–7.26 (2H,
m, Ar–C), 6.84 (1H, t, J ¼ 7.6 Hz, Ar–H), 3.05 (2H, broad s, CH2),
2.68 (2H, t, J ¼ 6.8 Hz, CH2); 13C-NMR (101 MHz; DMSO-d6) d:
169.3 (C]O), 162.6 (d, J¼ 240 Hz, Ar–C), 141.1 (d, J¼ 10 Hz, Ar–
C), 130.9 (d, J ¼ 10 Hz, Ar–C),115.4 (Ar–C), 110.3 (d, J ¼ 21 Hz,
Ar–C), 106.5 (d, J ¼ 27 Hz, Ar–C), 35.3 (CH2), 33.8 (CH2); HRMS:
m/z found, 183.0929. C9H12N2OF [MH]
+ requires, 183.0934.
tert-Butyl [3-(4-methylanilino)-3-oxopropyl]carbamate 2b.
1H-NMR (400 MHz; DMSO-d6) d: 9.80 (1H, broad s, N–H), 7.42
(2H, d, J¼ 8.8 Hz, Ar–H), 7.03 (2H, d, J¼ 8.8 Hz, Ar–H), 6.82 (1H,
broad s, N–H), 3.16 (2H, dt, J¼ 6.9 and 6.9 Hz, CH2), 2.39 (2H, t,
J¼ 6.9 Hz, CH2), 2.19 (3H, s, CH3), 1.33 (9H, s, (CH3)3); 13C-NMR
(101 MHz; DMSO-d6) d: 169.6 (C]O), 156.1 (C]O), 137.2 (Ar–
C), 132.4 (Ar–C), 129.5 (2  Ar–C), 119.6 (2  Ar–C), 78.1 (C-But),
37.2 (CH2), 37.1 (CH2), 28.8 (3  CH3), 21.0 (CH3).
tert-Butyl [3-(3-uoroanilino)-3-oxopropyl]carbamate 2c. 1H-
NMR (400 MHz; DMSO-d6) d: 10.11 (1H, broad s, N–H), 7.57 (1H,
d, J¼ 12.0 Hz, Ar–H), 7.28–7.25 (2H, m, Ar–H), 6.85–6.80 (2H, m,
Ar–H and N–H), 3.18 (2H, dt, J ¼ 7.2 and 7.2 Hz, CH2), 2.44 (2H,
t, J ¼ 7.2 Hz, CH2), 1.33 (9H, s, (CH3)3); 13C-NMR (101 MHz;
DMSO-d6) d: 170.3 (C]O), 162.6 (d, J ¼ 239 Hz, Ar–C), 156.1
(C]O), 141.4 (d, J ¼ 11 Hz, Ar–C), 130.7 (d, J ¼ 10 Hz, Ar–C),
115.3 (Ar–C), 109.9 (d, J ¼ 21 Hz, Ar–C), 106.3 (d, J ¼ 26 Hz, Ar–
C), 78.2 (C-But), 37.3 (CH2), 36.9 (CH2), 28.7 (3  CH3).Results & discussion
Analytical data was determined for all three tested exogenous
volatile organic compound standards i.e. aniline, 3-uoroani-
line and p-toluidine, by HS-SPME-GC-MS. Calibration graphs
were also obtained for all three VOCs over the concentration
range 0–100 mg mL1 with correlation coefficients, R2, of >0.99
in all cases. The limit of detection (LOD) and limit of quanti-
tation (LOQ), based on 3 or 10 standard deviations of the
blank, were determined for each VOC (Table 1). The inclusion of
a pre-concentration step, using SPME, allowed excellent LOD
and LOQ to be obtained using GC-MS (Table 1), typically 0.02 mg
mL1 and 0.06 mg mL1 for 3-uoroaniline.
Initially, the three potential enzyme substrates were tested
against a panel of 12 P. aeruginosa strains and 12 Burkholderia
cepacia complex strains (Table 2). All bacteria were tested in BHIThis journal is © The Royal Society of Chemistry 2020
Table 1 Analytical data for the quantification of exogenous volatile organic compounds by HS-SPME-GC-MS for analysis of sputum samples
from cystic fibrosis patients
VOC
GC retention
time (mins) Quantitative m/z
Linear range
(mg mL1) y ¼ mx + c R2 n
LOD (mg
mL1)
LOQ (mg
mL1)
Aniline 6.2 39–66–93 0–100 y ¼ 5146.7 + 83.4 0.9970 5 0.15 0.37
3-Fluoroanilinea 6.7 83–84–111 0–100 y ¼ 18 337x + 314.2 0.9970 5 0.02 0.06
p-Toluidine 7.6 77–106–107 0–100 y ¼ 11 163x + 417.3 0.9970 5 0.09 0.24
a Three 85 mm polyacrylate SPME bres were used during the analysis of cystic brosis patient sputum samples. Previous use of SPME technology
identied that bre degradation does not occur until around 200 injections; in this study SPME bres were used for a maximum of 125 injections to
ensure consistency between samples. Due to variability of adsorptive efficiency within the SPME, a new calibration for 3-uoroaniline was generated
each time a new bre was used; in addition, the LOD and LOQ was also re-calculated for each bre. The analytical data obtained was as follows:
SPME bre 1: y ¼ 18 694x + 308.5, R2 ¼ 0.9970, LOD 0.017 mg mL1 and LOQ ¼ 0.057 mg mL; SPME bre 2: y ¼ 18 374x + 254.9, R2 ¼ 0.9960, LOD
0.017 mg mL1 and LOQ ¼ 0.057 mg mL; and, SPME bre 3: y ¼ 18 136x + 267, R2 ¼ 0.9970, LOD 0.015 mg mL1 and LOQ ¼ 0.049 mg mL1.
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View Article Onlinebroth at a pre-incubation inoculum of 1  106 CFU mL1, and
substrates were added at 100 mg mL1, equivalent to 1.07 mmol
L1 aniline, 1.11 mmol L1 3-uoroaniline and 0.93 mmol L1
p-toluidine, using NMP as the solvent. All samples were incu-
bated overnight at 37 C prior to sampling viaHS-SPME-GC-MS.
Good activity was observed (typically > 20 mg mL1 VOC liber-
ated) for all P. aeruginosa strains across all 3 b-alanyl amino-
peptidase substrates. This supports the previous ndings in the
literature regarding activity in this species.29,30 There was some
variation in enzyme activity between the P. aeruginosa strains,
for instance using substrate 3-amino-N-(3-uorophenyl)prop-
anamide the AA44 strain produced an average of 38.5 mg mL1
(or 346 mmol L1) of its VOC product (3-uoroaniline), whereas
strain AUS52 produced an average of 19.8 mg mL1 (or 178 mmol
L1). In general terms, the 3-amino-N-(4-methylphenyl)prop-
anamide substrate evolved its VOC (i.e. p-toluidine) almost
always to a lower concentration (Table 2).
Enzyme activity was markedly less substantial in the B.
cepacia complex strains than in P. aeruginosa but was still
signicant enough for straightforward quantication. B. multi-
vorans, B. cenocepacia, B. cepacia, and B. stabilis all gave positive
results for b-alanyl aminopeptidase activity, with only B. viet-
namiensis testing negative in LMG strains 10 929 and 16 232
across all substrates. As was observed in the P. aeruginosa
strains, there was signicant variability in enzyme activity
between members of the same species when using the same
substrate. For instance, B. multivorans was the most tested
member of the B. cepacia complex strains with 5 strains tested,
and when tested with substrate 3-amino-N-(3-uorophenyl)
propanamide produced average VOC concentrations of between
1.2 mg mL1 and 12.8 mg mL1. Overall, the results from the b-
alanyl substrates were deemed to be acceptable (Table 2) despite
the lack of activity in B. vietnamiensis, however this is somewhat
offset given the minimal role B. vietnamiensis plays in cystic
brosis associated infections in comparison to B. multivorans,
B. cenocepacia, and B. cepacia.37
In order to ascertain which substrate would be most suitable
for further testing, a statistical analysis on the performance of
each b-alanyl substrate amongst the P. aeruginosa strains was
performed. A single factor ANOVA, with a p-value of 0.0002 (p#
0.05) was performed which indicated there was a statisticallyThis journal is © The Royal Society of Chemistry 2020signicant difference between the mean values of enzyme
activity, as assessed by the VOC concentration, between the 3
substrates. However, an ANOVA does not give an indication to
where the difference between the groups lies, and therefore
requires individual T-tests between paired groups to determine
which substrate produced the best results. Prior to T-tests, F-
tests were performed to determine equal or unequal variance
between the paired sample groups. An initial F-test was con-
ducted between the data from substrates 3-amino-N-(3-uo-
rophenyl)propanamide and 3-amino-N-(4-methylphenyl)
propanamide, which gave an F value of 17.4, and an F critical
value of 2.8; as the F value was greater than the F critical value,
we can reject the null hypothesis that sample variance is equal
between these datasets, and accept the alternative hypothesis
that the variance is unequal. Next, an F-test was carried out for
the data acquired from 3-amino-N-(3-uorophenyl)prop-
anamide and 3-amino-N-phenylpropanamide, giving subse-
quent F and F critical values of 2.2 and 2.8, respectively,
therefore indicating equal variance between the two datasets.
Finally, another F-test was conducted between substrates 3-
amino-N-(4-methylphenyl)propanamide and 3-amino-N-phe-
nylpropanamide, giving subsequent F and F critical values of 7.8
and 2.8, respectively, therefore indicating unequal variance
between the two datasets.
Following the implementation of F-test analyses, T-test
analyses were then performed on paired data sets. Firstly, a T-
test assuming unequal sample variances was conducted
between 3-amino-N-(3-uorophenyl)propanamide and 3-amino-
N-(4-methylphenyl)propanamide, giving a two tail p-value of
0.0009 meaning there is a statistically signicant difference (p <
0.05) between the means of the two datasets, with 3-amino-N-(3-
uorophenyl)propanamide producing a higher concentration
of VOC product from enzyme activity. Next a T-test assuming
equal sample variance was performed between 3-amino-N-(3-
uorophenyl)propanamide and 3-amino-N-phenyl-
propanamide, gave a two tail p-value of 0.3350 (p < 0.05),
meaning that no statistically signicant difference can be
inferred between these two datasets, and that the substrates
behave in a very similar manner in terms of VOC concentration
evolution. Lastly, a T-test assuming unequal samples variances
was carried out between 3-amino-N-(4-methylphenyl)RSC Adv., 2020, 10, 10634–10645 | 10639
Table 2 Preliminary b-alanyl substrate testing of P. aeruginosa strains and B. cepacia complex strains
ID number Strain ID
b-Alanyl substrates
Substrate: 3-amino-N-(3-
uorophenyl)propanamide
Substrate: 3-amino-N-(4-
methylphenyl) propanamide
Substrate: 3-amino-N-
phenylpropanamide
VOC: 3-uoroaniline VOC: p-toluidine VOC: aniline
Growth mg mL1 Growth mg mL1 Growth mg mL1
LMG 27632 P. aeruginosa AA44 + 38.5 (37.6, 39.3) + 21.0 (20.9, 21.2) + 36.4 (37.1, 35.8)
LMG 27631 P. aeruginosa AA43 + 33.4 (34.5, 32.4) + 22.0 (21.4, 22.6) + 27.3 (28.2, 26.5)
LMG 27629 P. aeruginosa AUS52 + 19.8 (19.8, 19.7) + 20.8 (20.1, 21.5) + 20.0 (20.3, 19.8)
LMG 27638 P. aeruginosa PA01 + 32.7 (32.3, 33.1) + 17.5 (17.5, 17.4) + 28.6 (28.8, 28.5)
LMG 27626 P. aeruginosa DK2 + 35.6 (35.4, 35.7) + 21.3 (21.2, 21.5) + 28.4 (27.4, 29.3)
LMG 27624 P. aeruginosa LES431 + 35.5 (36.3, 34.8) + 19.7 (19.3, 20.2) + 26.5 (26.0, 26.9)
LMG 27627 P. aeruginosa AES1R + 26.4 (25.6, 27.2) + 19.5 (19.1, 20.0) + 25.9 (26.4, 25.4)
LMG 27630 P. aeruginosa AA2 + 26.0 (25.9, 26.1) + 17.9 (18.1, 17.7) + 22.9 (23.6, 22.2)
LMG 27622 P. aeruginosa LESB58 + 24.9 (24.7, 25.1) + 21.1 (21.4, 20.7) + 28.4 (27.7, 29.1)
LMG 27625 P. aeruginosa C3719 + 23.9 (23.4, 24.3) + 18.4 (18.9, 17.9) + 22.5 (23.0, 21.9)
LMG 27623 P. aeruginosa LES400 + 20.7 (20.8, 20.6) + 18.0 (17.9, 18.2) + 22.1 (21.8, 22.4)
NCTC 12903 P. aeruginosa NCTC 12903 + 21.2 (20.7, 21.2) + 18.3 (17.9, 18.7) + 22.6 (23.1, 22.1)
LMG 18824 B. multivorans + 1.2 (1.2, 1.2) + 2.5 (2.5, 2.5) + 1.0 (1.0, 1.0)
LMG 14294 B. stabilis + 8.4 (8.2, 8.6) + 15.7 (15.4, 15.9) + 6.8 (6.6, 7.0)
LMG 18828 B. cenocepacia + 2.3 (2.3, 2.2) + 4.4 (4.4, 4.4) + 2.6 (2.5, 2.6)
LMG 18822 B. multivorans + 1.8 (1.8, 1.9) + 3.8 (3.9, 3.8) + 2.3 (2.3, 2.3)
LMG 18821 B. cepacia + 2.4 (2.4, 2.4) + 4.1 (4.1, 4.2) + 2.2 (2.2, 2.1)
LMG 16656 B. cenocepacia + 7.9 (8.1, 7.7) + 10.3 (10.4, 10.2) + 5.8 (5.8, 5.8)
LMG 10929 B. vietnamiensis + 0.0 (0.0, 0.0) + 0.0 (0.0, 0.0) + 0.0 (0.0, 0.0)
LMG 17588 B. multivorans + 12.8 (12.5, 13.2) + 21.0 (21.1, 20.9) + 10.6 (10.8, 10.5)
LMG 16660 B. multivorans + 1.5 (1.4, 1.5) + 3.4 (3.3, 3.4) + 2.3 (2.3, 2.3)
LMG 13010 B. multivorans + 2.8 (2.8, 2.8) + 8.9 (8.7, 9.2) + 5.5 (5.2, 5.9)
LMG 16232 B. vietnamiensis + 0.0 (0.0, 0.0) + 0.0 (0.0, 0.0) + 0.0 (0.0, 0.0)
LMG 1222 B. cepacia + 1.7 (1.7, 1.7) + 5.0 (4.9, 5.1) + 3.1 (3.0, 3.1)
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View Article Onlinepropanamide and 3-amino-N-phenylpropanamide, which gave
a two tail p-value of 0.0003 (p < 0.05), meaning there was
a statistically signicant difference between the average VOC
concentration evolution in our 12 P. aeruginosa strains between
these two substrates, with 3-amino-N-phenylpropanamide the
more productive of the two.
The results of all the T-test analyses indicated that whilst 3-
amino-N-(4-methylphenyl)-propanamide performed the poorest
out of the three b-alanyl aminopeptidase substrates, there was
no statistically signicant difference between the performance
of 3-amino-N-(3-uorophenyl)propanamide and 3-amino-N-
phenylpropanamide. However, from the initial calibration data
in Table 1, for the two VOCs produced by these compounds (3-
uoroaniline by 3-amino-N-(3-uorophenyl)propanamide, and
aniline by 3-amino-N-phenylpropanamide), the HS-SPME-GC-
MS method gave a lower limit of detection and limit of quan-
tication for 3-uoroaniline than aniline; therefore making 3-
amino-N-(3-uorophenyl)propanamide the most suitable
enzyme substrate for subsequent testing.
Subsequently a time study was performed using the enzyme
substrate, 3-amino-N-(3-uorophenyl)propanamide, to deter-
mine 3-uoroaniline evolution from a panel of 4 randomly
selected P. aeruginosa strains and 4 strains that represent the
sub-species of the B. cepacia complex. The results (Fig. 1), from
the time study on P. aeruginosa strains, were consistent10640 | RSC Adv., 2020, 10, 10634–10645(Fig. 1(a)), with increasing VOC evolution observed aer 6 h of
incubation in all tested strains; typical 3-uoroaniline concen-
trations ranging from 1.2 mg mL1 to 4.6 mg mL1, which was at
least 20 times higher than the estimated LOQ (Table 1). Results
for the B. cepacia complex strains were understandably less
impressive than those of the P. aeruginosa strains. None of the 4
strains were able to produce any VOC evolution following 6 h of
incubation, and only 2 of the 4 strains tested were able to
produce a detectable VOC signal following 8 h of incubation (B.
stabilis and B. cenocepacia). However, all 4 of the tested strains
were able to produce the VOC following 10 h of incubation;
typical 3-uoroaniline concentrations ranging from 0.3 mgmL1
to 2.2 mg mL1, which was at least 5 times higher than the
estimated LOQ (Table 1).
Detection of P. aeruginosa strains and B. cepacia complex
strains in sputum from patients with cystic brosis
A blind study was undertaken of 100 sputum samples collected
and analysed over the period of one calendar month from 78
distinct CF patients (49 male : 51 female). In addition, a further
5 samples were analyzed from CF patients who were post-lung
transplant. All generated data was evaluated post-analyses
(Table 3). The data identied that no false negative samples
were observed in the sputum sample data set. However, there
were 7 instances in which initial consideration of the exogenousThis journal is © The Royal Society of Chemistry 2020
Fig. 1 Evolution of 3-fluoroaniline using the enzyme substrate 3-amino-N-(3-fluorophenyl)propanamide with selected (a) P. aeruginosa strains
and (b) B. cepacia complex strains.
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View Article OnlineVOC data concluded a false positive result based on identica-
tion of b-alanyl aminopeptidase enzyme activity; this contra-
dicted the initial culture – MALDI-TOF-MS data which had not
detected the presence of P. aeruginosa. However, further inves-
tigation of these ‘false positive’ samples (samples 6, 13, 16, 17,
27, 34 and 85) by further culturing, isolation and MALDI-TOF-
MS conrmed the presence of a potentially b-alanyl amino-
peptidase positive organism that had been originally unre-
ported by the routine culture protocol for CF patient samples.
The subsequent analyses identied the b-alanyl aminopepti-
dase activity as being attributable to Serratia marcescens (sample
27), P. aeruginosa (samples 6, 16, 17 and 85), and a Pseudomonas
strain (sample 13 and 34); the latter could only be identied to
genus level viaMALDI-TOF-MS. All organisms isolated from the
re-cultured samples were then tested as pure colonies using 3-This journal is © The Royal Society of Chemistry 2020amino-N-(3-uorophenyl)propanamide and BHI broth as the
growth medium, and all were re-conrmed to be positive for b-
alanyl aminopeptidase activity.
Respiratory infections caused by P. aeruginosa are very
common in patients with CF and once chronic infection is
established, it is almost impossible to eradicate and is associ-
ated with increased mortality and morbidity.17 If infection can
be detected early, there is deemed to be a ‘window of opportu-
nity’ for treatment with antibiotics that can result in eradication
that is sustained for up to two years.17 Isolation of P. aeruginosa
using standard culture methods is not always straightforward as
the lung airways of patients with CF may contain several dozen
distinct bacterial species and well as fungi38 that can compete
with P. aeruginosa to form detectable colonies on culture media.
Isolation of colonies by culture can be particularly challenging ifRSC Adv., 2020, 10, 10634–10645 | 10641
Table 3 Comparison of exogenous volatile organic compound analysis by HS-SPME-GC-MS with culture –MALDI-TOF-MS of sputum samples
from cystic fibrosis patients
Sample ID
number Patient gender Patient age
Organisms identied from culture via
MALDI-TOF-MS
3-Fluoroaniline concentrationa (mg
mL1)
Notes8 h incubation 24 h incubation
1 M 51 Candida sp., P. uorescens, S. aureus 3.0 (2.8, 3.2) 23.7 (22.9, 24.5) b
2 F 10 Candida sp., E. dermatitidis 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
3 F 9 E. dermatitidis, P. mirabilis 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
4 F 9 Candida sp., E. dermatitidis, P. mirabilis 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
5 F 9 A. fumigatus, E. dermatitidis, P. mirabilis 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
6 F 9 E. coli, E. dermatitidis, P. mirabilis, S.
maltophilia, P. aeruginosa
0.5 (0.5, 0.5) 0.8 (0.8, 0.8) c
7 F 9 E. dermatitidis, P. mirabilis, S. maltophilia 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
8 F 9 A. fumigatus, Candida sp., E. dermatitidis,
P. mirabilis
0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
9 M 17 A. fumigatus, Serratia sp. 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
10 F 11 A. fumigatus, E. dermatitidis 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
11 F 11 A. fumigatus, E. dermatitidis, P.
aeruginosa
0.3 (0.3, 0.3) 33.7 (33.5, 33.9) b
12 M 19 A. fumigatus, E. dermatitidis, M. abscessus
complex
0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
13 M 19 A. fumigatus, Candida sp., E. dermatitidis,
Pseudomonas sp.
0.6 (0.7, 0.6) 2.5 (2.5, 2.6) d
14 M 7 Candida sp. 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
15 M 7 Candida sp., P. aeruginosa, Serratia sp. 0.4 (0.4, 0.4) 1.7 (1.7, 1.7) b
16 F 14 Candida sp., S. apiospermum, P.
aeruginosa
0.0 (0.0, 0.0) 0.4 (0.4, 0.4) c
17 F 14 S. apiospermum, P. aeruginosa 0.0 (0.0, 0.0) 4.0 (3.9, 4.2) c
18 F 14 Candida sp., P. aeruginosa, S.
apiospermum
5.1 (4.8, 5.4) 8.0 (8.3, 7.8) b
19 M 24 S. aureus 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
20 M 24 A. fumigatus, P. aeruginosa, S. aureus 0.6 (0.5, 0.6) 1.5 (1.5, 1.5) b
21 M 7 Candida sp., E. coli, E. dermatitidis 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
22 M 27 A. fumigatus, S. aureus, S. maltophilia 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
23 F 13 Achromobacter sp., E. dermatitidis 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
24 F 13 Achromobacter sp., E. dermatitidis 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
25 F 13 Achromobacter sp., E. dermatitidis 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
26 F 13 Achromobacter sp., Candida sp., E.
dermatitidis
0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
27 M 10 Candida sp., E. miricola, E. dermatitidis, S.
marcescens, M. abscessus complex
0.0 (0.0, 0.0) 3.0 (3.0, 3.0) e
28 M 10 Candida sp., E. dermatitidis 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
29 M 10 Candida sp. 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
30 M 10 Candida sp. 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
31 F 16 Candida sp., E. dermatitidis, Serratia sp.,
S. maltophilia
1.7 (1.4, 1.9) 4.8 (4.7, 5.0) b
32 F 16 Candida sp., E. dermatitidis, Serratia sp.,
M. llatzerense
2.2 (2.0, 2.1) 3.7 (3.7, 3.6) b
33 F 17 P. aeruginosa 6.5 (7.0, 6.0) 28.5 (26.6, 30.3) b
34 F 17 Pseudomonas sp. 8.7 (8.8, 8.6) 14.8 (14.6, 15.1) d
35 F 17 A. fumigatus, P. aeruginosa 1.7 (1.6, 1.8) 5.4 (5.2, 5.6) b
36 M 32 B. multivorans, Candida sp., S. aureus, S.
maltophilia
0.4 (0.4, 0.4) 2.0 (2.0, 2.1) b
37 F 23 Pandoraea sp., M. abscessus complex 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
38 M 24 P. aeruginosa 2.2 (2.0, 2.4) 5.4 (5.2, 5.7) b
39 F 27 P. aeruginosa 9.5 (8.9, 10.1) 17.9 (17.1, 18.7) b
40 F 27 P. aeruginosa 4.0 (3.7, 4.3) 13.5 (13.5, 13.6) b
41 F 32 P. aeruginosa, S. aureus 3.6 (3.6, 3.7) 7.1 (6.7, 7.4) b
42 F 34 A. fumigatus, Candida sp., P. aeruginosa 0.3 (0.3, 0.3) 5.3 (5.6, 5.1) b
43 M 38 A. fumigatus, B. multivorans, Candida sp.,
S. maltophilia, M. chelonae complex
0.3 (0.3, 0.3) 0.7 (0.7, 0.7) b
44 M 31 Candida sp., P. aeruginosa 2.7 (2.6, 2.9) 22.6 (21.8, 23.4) b
45 F 49 Candida sp., Pandoraea sp., P. aeruginosa 0.3 (0.3, 0.3) 0.5 (0.5, 0.5) b
46 F 65 Achromobacter sp. 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
10642 | RSC Adv., 2020, 10, 10634–10645 This journal is © The Royal Society of Chemistry 2020
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Table 3 (Contd. )
Sample ID
number Patient gender Patient age
Organisms identied from culture via
MALDI-TOF-MS
3-Fluoroaniline concentrationa (mg
mL1)
Notes8 h incubation 24 h incubation
47 M 33 Candida sp., P. aeruginosa, S. maltophilia 2.5 (2.3, 2.6) 5.1 (5.0, 5.2) b
48 M 31 B. multivorans, Candida sp., P.
aeruginosa
2.8 (2.7, 3.0) 4.8 (4.5, 5.1) b
49 F 8 N/A 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
50 F 24 Candida sp., S. agalactiae (GpB) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
51 M 29 E. coli, P. aeruginosa, M. llatzerense, M.
chelonae complex
2.9 (2.9, 2.9) 3.7 (3.7, 3.7) b
52 M 22 E. dermatitidis, P. aeruginosa, M.
abscessus complex
0.3 (0.3, 0.4) 0.5 (0.5, 0.5) b
53 M 35 B. multivorans, Candida sp., P.
aeruginosa
0.4 (0.3, 0.4) 1.0 (0.9, 1.1) b
54 M 8 Neisseria elongata 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
55 F 19 A. fumigatus, S. aureus 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
56 M 29 Candida sp., P. aeruginosa 7.8 (7.9, 7.8) 9.3 (9.2, 9.4) b
57 F 30 Achromobacter sp., P. aeruginosa 4.7 (4.4, 5.0) 8.2 (8.0, 8.4) b
58 M 62 N/A 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
59 F 46 P. aeruginosa 13.5 (12.8, 14.1) 27.9 (28.5, 27.2) b
60 M 42 A. fumigatus, Candida sp., P. aeruginosa,
S. aureus
0.4 (0.3, 0.4) 0.7 (0.7, 0.7) b
61 F 40 Candida sp., P. aeruginosa, M. llatzerense 5.7 (5.5, 5.9) 21.0 (20.6, 21.4) b
62 F 44 P. aeruginosa 4.0 (3.8, 4.3) 10.9 (10.9, 10.9) b
63 F 14 P. aeruginosa 14.6 (14.9, 14.4) 22.3 (21.8, 22.7) b
64 M 49 A. fumigatus, Candida sp., S. maltophilia 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
65 M 35 A. fumigatus, Candida sp., P. aeruginosa 8.2 (8.1, 8.3) 25.4 (25.8, 25.0) b
66 M 38 P. aeruginosa 4.3 (4.2, 4.3) 17.0 (16.6, 17.4) b
67 M 12 N/A 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
68 F 48 Candida sp., S. aureus 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
69 M 36 Candida sp., P. aeruginosa 6.7 (6.6, 6.9) 21.8 (22.1, 21.5) b
70 F 24 A. fumigatus, E. dermatitidis, H.
inuenzae, S. aureus
0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
71 M 19 P. aeruginosa, M. abscessus complex 6.3 (6.3, 6.2) 9.1 (8.8, 9.5) b
72 M 23 Candida sp., P. aeruginosa, S.
maltophilia, M. abscessus complex
0.6 (0.6, 0.6) 1.1 (1.1, 1.1) b
73 M 31 E. dermatitidis, P. aeruginosa 12.7 (12.9, 12.5) 22.5 (22.7, 22.3) b
74 M 34 Candida sp., S. aureus 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
75 F 14 A. fumigatus, Candida sp., E. dermatitidis,
P. aeruginosa
0.4 (0.4, 0.4) 1.0 (1.1, 1.0) b
76 M 37 Achromobacter sp. 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
77 M 29 Candida sp., E. dermatitidis, Rothia sp., S.
maltophilia
0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
78 F 70 Candida sp., P. aeruginosa, S. aureus 0.3 (0.3, 0.3) 0.5 (0.6, 0.5) b
79 M 25 Candida sp., E. dermatitidis, P.
aeruginosa, Rothia sp.
0.3 (0.3, 0.3) 5.5 (5.4, 5.7) b
80 M 24 P. aeruginosa, M. abscessus complex 0.9 (0.9, 1.0) 25.0 (24.6, 25.5) b
81 F 21 Achromobacter sp., Candida sp., P.
aeruginosa
0.5 (0.5, 0.5) 1.2 (1.1, 1.2) b
82 F 27 Candida sp., H. inuenzae, P. aeruginosa,
Serratia sp., S. aureus
2.7 (2.6, 2.8) 4.6 (4.5, 4.7) b
83 F 35 Candida sp., K. oxytoca, P. aeruginosa, S.
aureus
0.3 (0.3, 0.3) 1.2 (1.1, 1.2) b
84 F 39 B. multivorans, Candida sp., S.
maltophilia
0.3 (0.3, 0.4) 0.7 (0.7, 0.8) b
85 M 9 P. aeruginosa 24.5 (24.7, 24.2) 32.9 (34.1, 31.7) c
86 F 26 A. fumigatus, S. aureus 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
87 F 66 Candida sp., S. aureus 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
88 M 32 Candida sp., S. aureus 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
89 M 47 A. fumigatus, S. maltophilia, M. abscessus
complex
0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
90 F 18 A. fumigatus, Candida sp., P. aeruginosa 4.7 (4.6, 4.8) 24.4 (33.9, 34.8) b
This journal is © The Royal Society of Chemistry 2020 RSC Adv., 2020, 10, 10634–10645 | 10643
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Table 3 (Contd. )
Sample ID
number Patient gender Patient age
Organisms identied from culture via
MALDI-TOF-MS
3-Fluoroaniline concentrationa (mg
mL1)
Notes8 h incubation 24 h incubation
91 M 21 B. multivorans, Candida sp., P.
aeruginosa, Serratia sp.
2.1 (2.1, 2.1) 8.5 (7.0, 9.9) b
92 F 25 Candida sp., P. aeruginosa 2.7 (2.6, 2.8) 4.5 (4.3, 4.7) b
93 F 26 Candida sp., P. aeruginosa 7.8 (7.6, 8.1) 8.3 (7.9, 8.7) b
94 F 49 Candida sp., S. aureus 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
95 M 35 Candida sp., P. aeruginosa 0.5 (0.4, 0.5) 1.3 (1.4, 1.2) b
96 M 34 S. aureus 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
97 F 22 Candida sp., P. aeruginosa 0.3 (0.3, 0.3) 0.7 (0.7, 0.8) b
98 M 47 Candida sp., P. aeruginosa 1.9 (2.0, 1.7) 3.8 (3.7, 4.0) b
99 M NR Achromobacter sp. 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
100 M NR Candida sp. 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
101 F 18 P. aeruginosa 7.1 (6.9, 7.4) 26.4 (26.9, 26.0) b,f
102 M 38 Candida sp., S. aureus 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) f
103 F 37 Achromobacter sp., A. fumigatus, P.
aeruginosa
17.0 (17.5, 16.5) 23.1 (26.2, 20.1) b,f
104 M 28 Achromobacter sp., P. aeruginosa 6.1 (6.5, 5.8) 8.4 (8.7, 8.1) b,f
105 F 20 Candida sp., S. aureus 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) f
a Mean (individual value). b b-Alanine activity detected + causative organism identied in routine culture testing. c P. aeruginosa initially missed by
routine culture; positive b-alanine activity determined following subsequent pure isolate testing. d Pseudomonas sp. initially missed by routine
culture; positive b-alanine activity determined following subsequent pure isolate testing. e S. marcescens initially missed by routine culture;
positive b-alanine activity determined following subsequent pure isolate testing. f Post lung transplant sample. NR ¼ not recorded. NA ¼ not
applicable; no organisms detected.
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View Article Onlinethe abundance of P. aeruginosa is very low, relative to other co-
inhabitants of the lung. This is likely to be the case when P.
aeruginosa rst colonizes the airways prior to chronic coloni-
zation and infection. To circumvent this problem, Billard-
Pomares et al. developed a quantitative polymerase chain
reaction (PCR) method to detect P. aeruginosa in sputum
samples and demonstrated a detection limit of around 15 CFU
mL1 of sputum.39 Using this highly-sensitive method, they
were able to demonstrate detection of P. aeruginosa in 10/33
sputum samples that were negative using standard culture
methods. They concluded that this method may be a very useful
tool in association with bacterial culture for the diagnosis of
early P. aeruginosa colonization and the monitoring of P. aeru-
ginosa eradication aer antimicrobial therapy in young CF
patients.39 One limitation of PCR methods, as highlighted by
the authors, was the possibility that dead or non-viable P. aer-
uginosa would be detected and this could be particularly prob-
lematic if PCR is used to monitor the outcome of eradication
therapy – which is another scenario where the bacterial load of
P. aeruginosa may be low and more challenging to detect using
standard culture methods.Conclusions
To the best of our knowledge, this is the rst demonstration of
detection of P. aeruginosa by use of a custom-designed substrate
to liberate a detectable VOC. The test includes a selective
enrichment broth that can potentially accommodate a high
volume of sputum resulting in high sensitivity. In comparison,10644 | RSC Adv., 2020, 10, 10634–10645with standard culture methods, this new culture method
demonstrated 100% sensitivity and resulted in the detection of
six additional isolates of Pseudomonas species (four of which
were conrmed as P. aeruginosa) that were initially missed by
culture. The very high negative predictive value (100% in this
study) means that such an assay could be appropriate as
a screening technique for patients who are not yet colonized by
this pathogen. Future work will focus on a simplied means for
detection of the VOC liberated by b-alanyl aminopeptidase
activity (e.g. using a colorimetric indicator) to obviate the
requirement for sophisticated instrumentation.Conflicts of interest
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